A new paradigm evaluating cost per cure of HCV infection in the UK

BACKGROUND: New interferon (IFN)-free treatments for hepatitis C are more effective, safer but more expensive than current IFN-based therapies. Comparative data of these, versus current first generation protease inhibitors (PI) with regard to costs and treatment outcomes are needed. We investigated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatol Med Policy
Main Authors: Barclay, Stephen T., Cooke, Graham S., Holtham, Elizabeth, Gauthier, Aline, Schwarzbard, Jeremie, Atanasov, Petar, Irving, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898515/
https://ncbi.nlm.nih.gov/pubmed/30288304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41124-016-0002-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados